Endocrine Risk Factors for Cognitive Impairment

Cognitive impairment, including Alzheimer's disease and other kinds of dementia, is a major health problem in older adults worldwide. Although numerous investigators have attempted to develop effective treatment modalities or drugs, there is no reasonably efficacious strategy for preventing or...

Full description

Bibliographic Details
Main Author: Jae Hoon Moon
Format: Article
Language:English
Published: Academya Publishing Co. 2016-06-01
Series:Endocrinology and Metabolism
Subjects:
Online Access:http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-31-185.pdf
id doaj-31cae733e5a74ecd8c0b3f475296f453
record_format Article
spelling doaj-31cae733e5a74ecd8c0b3f475296f4532020-11-24T23:37:52ZengAcademya Publishing Co.Endocrinology and Metabolism2093-596X2093-59782016-06-0131218519210.3803/EnM.2016.31.2.18520208Endocrine Risk Factors for Cognitive ImpairmentJae Hoon MoonCognitive impairment, including Alzheimer's disease and other kinds of dementia, is a major health problem in older adults worldwide. Although numerous investigators have attempted to develop effective treatment modalities or drugs, there is no reasonably efficacious strategy for preventing or recovering from cognitive impairment. Therefore, modifiable risk factors for cognitive impairment have received attention, and the growing literature of metabolic risk factors for cognitive impairment has expanded from epidemiology to molecular pathogenesis and therapeutic management. This review focuses on the epidemiological evidence for the association between cognitive impairment and several endocrine risk factors, including insulin resistance, dyslipidemia, thyroid dysfunction, vitamin D deficiency, and subclinical atherosclerosis. Researches suggesting possible mechanisms for this association are reviewed. The research investigating modifiable endocrine risk factors for cognitive impairment provides clues for understanding the pathogenesis of cognitive impairment and developing novel treatment modalities. However, so far, interventional studies investigating the beneficial effect of the "modification" of these "modifiable risk factors" on cognitive impairment have reported variable results. Therefore, well-designed, randomized prospective interventional studies are needed.http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-31-185.pdfCognitionDementiaRisk factors
collection DOAJ
language English
format Article
sources DOAJ
author Jae Hoon Moon
spellingShingle Jae Hoon Moon
Endocrine Risk Factors for Cognitive Impairment
Endocrinology and Metabolism
Cognition
Dementia
Risk factors
author_facet Jae Hoon Moon
author_sort Jae Hoon Moon
title Endocrine Risk Factors for Cognitive Impairment
title_short Endocrine Risk Factors for Cognitive Impairment
title_full Endocrine Risk Factors for Cognitive Impairment
title_fullStr Endocrine Risk Factors for Cognitive Impairment
title_full_unstemmed Endocrine Risk Factors for Cognitive Impairment
title_sort endocrine risk factors for cognitive impairment
publisher Academya Publishing Co.
series Endocrinology and Metabolism
issn 2093-596X
2093-5978
publishDate 2016-06-01
description Cognitive impairment, including Alzheimer's disease and other kinds of dementia, is a major health problem in older adults worldwide. Although numerous investigators have attempted to develop effective treatment modalities or drugs, there is no reasonably efficacious strategy for preventing or recovering from cognitive impairment. Therefore, modifiable risk factors for cognitive impairment have received attention, and the growing literature of metabolic risk factors for cognitive impairment has expanded from epidemiology to molecular pathogenesis and therapeutic management. This review focuses on the epidemiological evidence for the association between cognitive impairment and several endocrine risk factors, including insulin resistance, dyslipidemia, thyroid dysfunction, vitamin D deficiency, and subclinical atherosclerosis. Researches suggesting possible mechanisms for this association are reviewed. The research investigating modifiable endocrine risk factors for cognitive impairment provides clues for understanding the pathogenesis of cognitive impairment and developing novel treatment modalities. However, so far, interventional studies investigating the beneficial effect of the "modification" of these "modifiable risk factors" on cognitive impairment have reported variable results. Therefore, well-designed, randomized prospective interventional studies are needed.
topic Cognition
Dementia
Risk factors
url http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-31-185.pdf
work_keys_str_mv AT jaehoonmoon endocrineriskfactorsforcognitiveimpairment
_version_ 1725518643076268032